Abstract 142P
Background
To investigate the incidence and prognosis of intra-abdominal infectious complications (IaIC) after laparoscopic and open radical gastrectomy for gastric cancer.
Methods
The data of patients who underwent radical gastrectomy for gastric cancer at the Fujian Medical University Union Hospital from January 2000 to December 2014, retrospectively LAG and OG were used. 1:1 propensity score matching (PSM) was used to reduce biases. The incidence and prognosis of postoperative IaIC in the two groups were analyzed.
Results
The incidence of IaIC after OG and LAG was 4.1% and 5.1%, respectively(p=0.264). Cox multivariate analysis showed that IaIC was an independent risk factor for overall survival (OS) of patients undergoing gastrectomy (HR: 1.65, 95%CI: 1.23-2.20, p<0.001). Analysis also showed that LAG was an independent protective factor for OS with IaIC (HR 0.54, 95%CI: 0.31-0.96, p=0.036), and tumor diameter ≥ 50 mm (p=0.01) and pTNM III stage (p<0.001) were independent risk factors. After PSM, the five-year OS rate of patients with IaIC in the LAG was higher than that in the OG (51.1% vs. 32.4%, p=0.042). The independent preoperative risk factors for IaIC include male (OR 1.82, p=0.046) and BMI ≥ 25 (OR 1.88, p=0.021). Among patients with IaIC, the prognostic nutritional index (PNI) in OG group was similar to that in LAG group before operation (p=0.220), but lower than that in LAG group on the 1st, 3rd, and 5th day after surgery (p<0.05).
Conclusions
Compared to OG, LAG can improve the prognosis of patients with postoperative IaIC. For high-risk patients with IaIC, LAG is recommended.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
393P - Clinical characteristics and prognosis of patients with pulmonary mucoepidermoid carcinoma: A SEER-based analysis
Presenter: Lingxiao Qiu
Session: e-Poster Display Session
394P - Apatinib plus etoposide capsules as third-line or further-line treatment for extensive stage small cell lung cancer patients: A multicenter, single arm, phase II clinical trial
Presenter: Zhen He
Session: e-Poster Display Session
395P - Afatinib in Asian and non-Asian patients (pts) with EGFR mutation positive (EGFRm+) NSCLC harboring major uncommon mutations
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
396P - Efficacy and safety of S-1 in elderly patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy: A subgroup analysis of the EAST-LC
Presenter: James Chih-Hsin Yang
Session: e-Poster Display Session
397P - A phase I cohort expansion trial of OBI-833 in non-small cell lung cancer patients
Presenter: Ching-Liang Ho
Session: e-Poster Display Session
398P - Real-world mechanism of crizotinib-resistance in MET exon 14 skipping mutations non-small-cell lung cancer using next generation sequencing: A multicenter study
Presenter: Dong Wang
Session: e-Poster Display Session
399P - Real-world insights into patients (pts) with advanced NSCLC and MET alterations
Presenter: Marisa Bittoni
Session: e-Poster Display Session
400P - Sequential afatinib and osimertinib in real-world EGFR mutation positive (EGFRm+) NSCLC: Final analysis of Asian patients in the GioTag study
Presenter: Maximilian J. Hochmair
Session: e-Poster Display Session
401P - A prospective, phase II trial of low-dose afatinib monotherapy for patients with EGFR, mutation-positive, non-small cell lung cancer (TORG1632)
Presenter: Satoshi Igawa
Session: e-Poster Display Session
402P - Efficacy and safety of sintilimab plus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC)
Presenter: Zhehai Wang
Session: e-Poster Display Session